Core Insights - Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][3] - The company plans to file its 10K report by the end of March, which will include a more detailed corporate update [2] Company Overview - Aclarion leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [3] - The company's primary product, Nociscan, is a SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [3] - Nociscan processes MRS data from MRI machines to extract and quantify chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [3]

Core Insights - Aclarion, Inc. is expanding the access of its Nociscan technology across multiple sites in New York and New Jersey to address the growing demand for chronic low back pain solutions [1][2] - The expansion is supported by enhanced remote operations capabilities and increased availability of Magnetic Resonance Spectroscopy (MRS) within RadNet [1][2] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary AI algorithms to assist physicians in identifying chronic low back pain locations [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][5] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge [4] - The Nociscan solution quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][5] Strategic Partnerships - Lenox Hill Radiology operates 79 locations in New York and has adopted Nociscan to enhance access for leading spine physicians [2][3] - New Jersey Imaging Network, with 33 locations, was the first in NJ to adopt Nociscan, facilitating support for local and out-of-market referrals [3]

Core Insights - Aclarion, Inc. has established a commercial agreement with Scripps Health to expand access to its Nociscan technology for chronic low back pain diagnosis in the San Diego area [1][2][3] - Nociscan utilizes MR Spectroscopy and AI to help physicians identify the sources of chronic low back pain, distinguishing between painful and nonpainful discs [3][5] - The agreement will benefit over 3.2 million people in the greater San Diego Metro area, enhancing the capabilities of leading spine physicians at Scripps Health [1][2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, leveraging biomarkers and proprietary AI algorithms [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist physicians in diagnosing disc-related pain [3][5] - The technology processes MRS data from MRI machines to quantify chemical biomarkers associated with disc pain, providing critical insights for treatment optimization [5][6] Industry Context - Chronic low back pain is a significant global healthcare issue, affecting approximately 266 million people worldwide [3] - The partnership with Scripps Health is expected to enhance diagnostic capabilities and treatment strategies for patients suffering from chronic low back pain [2][3]

Core Points - Aclarion, Inc. has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025, to March 5, 2025, to solicit additional votes on proposals outlined in the definitive proxy statement filed with the SEC on February 3, 2025 [2][5][6] - The reconvened Special Meeting will take place at the company's corporate office in Broomfield, Colorado, and stockholders as of the record date of January 6, 2025, are encouraged to vote promptly [3][4] - Proxies submitted for the Special Meeting will remain valid unless revoked, and stockholders can change their votes until March 4, 2025, at 11:59 p.m. Mountain Time [4] Company Overview - Aclarion, Inc. is a healthcare technology company that utilizes Magnetic Resonance Spectroscopy (MRS) and a proprietary biomarker to enhance clinical treatments for low back and neck pain, addressing a market valued at $134.5 billion in the U.S. [7] - The company is integrating Artificial Intelligence (AI) into its quality control processes to identify poor MRS study data and is exploring AI and machine learning applications to analyze spectroscopy data for better clinical outcome associations [7]

Core Insights - Aclarion, Inc. is participating in the 2025 Spine Summit to showcase its innovative NOCISCAN technology aimed at addressing chronic low back pain [1][3] Company Overview - Aclarion is a healthcare technology company that utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying chronic low back pain [1][7] - The company’s NOCISCAN platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [4][7] Technology and Innovation - NOCISCAN combines Magnetic Resonance Spectroscopy (MRS) with augmented intelligence to provide critical insights into the location of low back pain, enabling tailored treatment plans for patients [2][4][8] - The platform quantifies chemical biomarkers associated with disc pain, enhancing diagnostic accuracy when used alongside other tools [4][10] Event Participation - Dr. Nicholas Theodore, a prominent orthopedic surgeon, will present at the Spine Summit, discussing the transformative impact of NOCISCAN on spine surgery [2][9] - The presentation is scheduled for February 21, 2025, at the JW Marriott Tampa Water Street [9]

Core Insights - Aclarion, Inc. has received a Notice of Allowance for its 24th US patent, expanding its ability to use Magnetic Resonance Spectroscopy (MRS) to identify propionic acid (PA) throughout the body, which may indicate potential sources of infection and pain [1][6][2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing MRS, proprietary signal processing techniques, and augmented intelligence algorithms to optimize clinical treatments [4] - The company's Nociscan platform is the first evidence-supported SaaS solution designed to help physicians differentiate between painful and non-painful discs in the lumbar spine [4] Patent and Technology Development - The new patent allows Aclarion to measure propionic acid as a biomarker for identifying potential infections and pain beyond just discogenic low back pain [6][2] - MRS is a capability of MRI scanners that provides spectral data on various chemical biomarkers, but traditional MRS post-processing can be challenging; Aclarion's patents address these challenges, enhancing the reliability and quality of spectral data [2][6] Implications of the Patent - The patent's implications are significant, as it positions Aclarion to commercialize MRS applications more broadly, potentially impacting the diagnosis and treatment of various conditions associated with propionic acid [2][6]

Core Insights - Aclarion, Inc. is conducting the pivotal CLARITY trial to evaluate the clinical and economic value of its Nociscan technology for chronic low back pain surgery [1][2] - Nociscan aims to become the gold standard in identifying sources of low back pain using MR Spectroscopy and AI [1][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][5] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful lumbar discs [3][6] Clinical Trial Details - The CLARITY trial is a randomized, multi-center study involving 300 patients scheduled for surgical treatment of discogenic low back pain [2][3] - The trial will compare surgical outcomes based on Nociscan results, with a primary endpoint of back pain change measured on a 100mm VAS scale at 12 months [2][3] Market Context - Approximately 266 million people globally suffer from degenerative spine disease and low back pain, highlighting the significance of Aclarion's Nociscan solution [3][6] - The trial is fully funded and led by Dr. Nicholas Theodore from Johns Hopkins, indicating strong institutional support [2][3]

Core Insights - Aclarion, Inc. has secured nearly $20 million in gross proceeds to fully fund its pivotal CLARITY trial, which aims to validate the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain patients [1][2] - The CLARITY trial is a prospective, randomized, multicenter study enrolling 300 patients, led by Dr. Nicholas Theodore from Johns Hopkins, and builds on existing peer-reviewed data supporting Nociscan's potential [2][3] - Nociscan is positioned as a groundbreaking solution in the chronic low back pain market, utilizing Magnetic Resonance Spectroscopy (MRS) and augmented intelligence to differentiate between painful and nonpainful discs [3][5] Funding and Trial Details - The funding secured since January 1, 2025, ensures the completion of the CLARITY trial, which is critical for potentially unlocking broader payer coverage for Nociscan [2] - The trial aims to demonstrate Nociscan's clinical and economic value in spine surgery, with a focus on matching surgical interventions to specific discs identified as pain sources [2][3] Market Context - Chronic low back pain affects approximately 266 million people globally, highlighting the significant healthcare challenge and the potential market for Aclarion's Nociscan solution [3] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively assist physicians in identifying the source of low back pain, achieving a reported 97% surgical success rate at one year follow-up when treating identified pain-positive discs [3][5]

Core Insights - Aclarion, Inc. is participating in the Selby Spine Conference to showcase its NOCISCAN platform, which utilizes biomarkers and AI algorithms to assist in identifying chronic low back pain locations [1][2] - Dr. Sigurd Berven will present on how NOCISCAN can help physicians detect biomarkers that are not visible through traditional imaging methods, enabling personalized treatment plans for patients [2][4] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to optimize clinical treatments [6] - NOCISCAN is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine, providing critical insights for treatment strategies [4][6] Presentation Details - The presentation titled "MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard" will highlight the innovative capabilities of NOCISCAN [2][3] - NOCISCAN combines MR Spectroscopy with augmented intelligence to set a new standard for noninvasive diagnostics in spine surgery and chronic pain management [3] Market Context - Chronic low back pain affects approximately 266 million people globally, indicating a significant healthcare challenge that Aclarion aims to address with its technology [4]

Core Viewpoint - Aclarion, Inc. (ACON) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - Aclarion's rising earnings estimates and the subsequent rating upgrade suggest an improvement in the company's underlying business, likely leading to increased stock prices [5][11]. Earnings Estimate Revisions - For the fiscal year ending December 2024, Aclarion is expected to earn -$0.79 per share, representing a 91% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Aclarion has increased by 20.2%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Aclarion's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10][11].